Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanism

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have shown promise in clinical trials, their underlying molecular mechanisms remain unclear…